First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-del(17p)

Trial Profile

First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-del(17p)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Allopurinol; Cyclophosphamide; Fludarabine; Valaciclovir
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results (n=23) presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 Results (n=23) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 21 Mar 2016 Planned primary completion date changed from 1 Feb 2022 to 1 Mar 2022, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top